Navigation Links
FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) System
Date:5/11/2010

BETHLEHEM, Pa., May 11 /PRNewswire/ -- The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO )

Used in hospitals and healthcare centers to treat a wide variety of bacterial infections, Cefepime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. The availability of 1g and 2g Cefepime in the DUPLEX® System will mean faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.

"Making 1g and 2g Cefepime available to healthcare workers in B. Braun's DUPLEX® Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy," said Rob Albert, Vice President of Marketing for B. Braun Medical Inc.

The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.

Healthcare workers administering 1g or 2g Cefepime through DUPLEX® simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Customers interested in obtaining more information can call: 1-888-422-7286 (1-888-4BBRAUN).

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals.  For more information, call 800-227-2862, e-mail us at inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.


'/>"/>
SOURCE B. Braun Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. FDA Approves Natazia(TM), a New Oral Contraceptive for the Prevention of Pregnancy
2. FDA Approves New Combination Product Oral Contraceptive
3. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
4. FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
5. FDA Approves New Device for Adults with Severe and Persistent Asthma
6. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
7. FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device
8. FDA Approves First Totally Implanted Hearing System
9. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
10. FDA Approves Name Change for Heartburn Drug Kapidex
11. FDA Approves First Generic Tamsulosin to Treat Enlarged Prostate Gland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
(Date:1/18/2017)... JAKARTA, Indonesia , Jan. 17, 2017  With an annual growth ranging from ... for success. CPhI SEA (Jakarta International Expo, March 22-24, 2017) serves the ... What,s new at CPhI SEA 2017? Investment Forum ... Distributors, network Richer conference content Enhanced business ... Reading ...
(Date:1/18/2017)... , Jan. 18, 2017   Seno Medical ... of diagnosing breast cancer through the development of an ... Steve Miller as SVP of Engineering. Mr. ... Realization at FUJIFILM SonoSite, with headquarters in ... majority of his 30-year career to the development of ...
Breaking Medicine Technology:
(Date:1/18/2017)... West Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... April as a fund raiser for Smile Train, an international charity that provides free ... is a hobby of mine and in the past I have run to support ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Dr. Farhan ... family, cosmetic and implants dentistry. His modern dental practice has two convenient office locations ... a 2017 Top Rated Dentist for the Alexandria area. This award confirms ...
(Date:1/18/2017)... ... 18, 2017 , ... During pregnancy, women are at an ... those dental problems can increase the risk of pregnancy complications. Unfortunately, according to ... to get the dental care they need. Agoura Hills dentist, Philip Shindler ...
(Date:1/17/2017)... ... January 17, 2017 , ... In the crowded Ath-leisure ... a stand-out company for several differences from other mainstream brands. , Firstly, ... this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . It allows them to ...
(Date:1/17/2017)... ... 2017 , ... Kevin Harrington (one of the original Sharks from mega-hit reality ... the topic of Beauty and Personal Care. , Everyone makes New ... to commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro ...
Breaking Medicine News(10 mins):